Samples were incubated in the dark at room temperature for 30 min
PMID 2137911 Subcutaneous injection-site pharmacokinetics FDA review
Such comprehensive action often leads to more effective weight loss results compared to other treatments
Some participants lost over 30%
When combined with existing therapies such as gilteritinib or venetoclax/azacitidine, TMQ0153 shows synergistic effects, offering a promising combination approach to improve treatment outcomes in AML
The protein sample was extracted from membrane by adding a 2 solubilization buffer containing 20 mM HEPES pH 7.5, 500 mM NaCl, 2% (w/v) n-dodecyl-beta-D-maltopyranoside (DDM, Affymetrix), 0.4% (w/v) cholesteryl hemisuccinate (CHS, Sigma), and 2% (w/v) glycerol for 3 h at 4 C